Arkansas
Prescription drug spending and prescribing in Arkansas, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $2.7B for prescriptions written in Arkansas, the 32nd most of 52 states and territories, and 4.7% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $2.7B
- Medicaid drugs, 2025: $499M
- Opioid share of claims: 4.7%
- Life-science raises, 2 years: $2.4M
Opioid share of Part D claims, 2024
Arkansas outlined; every state in quartiles. Click a state to compare.
- Up to 3.2%
- 3.2% to 3.7%
- 3.7% to 4.3%
- Over 4.3%
| Share of Part D claims | Arkansas | United States | Difference |
|---|---|---|---|
| Opioids | 4.7% | 3.5% | +34% |
| Antibiotics | 4.3% | 4.4% | −4% |
| Antipsychotics | 1.5% | 1.7% | −14% |
| Drug | Against national rate | Claims |
|---|---|---|
| Propafenone HCl | 3.2× | 10,198 |
| Promethazine HCl | 2.6× | 41,241 |
| Sotalol HCl | 2.4× | 32,733 |
| Prasugrel HCl | 2.1× | 8,407 |
| Naloxone HCl | 2.0× | 17,609 |
| Cyproheptadine HCl | 2.0× | 5,428 |
| Sucralfate | 2.0× | 55,493 |
| Hydrocodone/acetaminophen | 1.9× | 463,721 |
| Tizanidine HCl | 1.9× | 157,118 |
| Cefdinir | 1.8× | 50,444 |
- ASAP Imaging, LLC$1.1M · Other health care · Apr 7, 2026
- OurPharma Holdings LLC$500K · Other health care · Jul 23, 2025
- Site Saver, Inc.$496K · Other health care · Mar 10, 2026
- Glucose Health, Inc.$173K · Other health care · Oct 7, 2026
- Glucose Health, Inc.$60K · Other health care · Oct 19, 2026
- Glucose Health, Inc.$30K · Other health care · Oct 6, 2026
- Glucose Health, Inc.$12K · Other health care · Oct 6, 2026
- Plaintiff States and FTC v. CVET TOPCO, L.P. et al.2026 · Pending
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Alabama et al. v. Endo International, No. 3:19-cv-04157 (N.D. Cal. July 19, 2019)2019 · Settled
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Florida et al. v. Abbott Laboratories et al., No. 1:08-cv-00155-SLR (D.Del. 2007)2007 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
Alabama · Alaska · Arizona · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG